Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness - PubMed

Affiliations

• PMID: 20371230
• DOI: 10.1016/j.ejphar.2009.12.043

Review

Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness

Anne Lesage et al. Eur J Pharmacol. 2010.

Abstract

Metabotropic glutamate mGlu(1) receptors play a modulatory role in the nervous system. They enhance cell excitability, modulate synaptic neurotransmission and are involved in synaptic plasticity. During the last 10 years, several selective metabotropic glutamate mGlu(1) receptor competitive antagonists and potentiators have been discovered. These pharmacological tools, together with early and later work in metabotropic glutamate mGlu(1) receptor mutant mice have allowed studying the role of the receptor in various aspects of psychiatric illnesses such as anxiety, depression and schizophrenia. We here review the data on selective metabotropic glutamate mGlu(1) receptor antagonists in support of their potential as anxiolytic and antidepressant treatments. We propose a rationale for the development of metabotropic glutamate mGlu(1) receptor positive allosteric modulators for the treatment of schizophrenia. Potential side effects of blockade and activation of metabotropic glutamate mGlu(1) receptors are addressed, with special focus on the differential effects of metabotropic glutamate mGlu(1) receptor antagonists in cognition models with positive reinforcement versus those that use aversive learning procedures. Further development of negative allosteric modulators and more drug-like positive allosteric modulators will be required in order to decipher the therapeutic efficacy and safety margin of these compounds in the clinic.

Similar articles

• Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.

  Palucha A, Pilc A. Palucha A, et al. Pharmacol Ther. 2007 Jul;115(1):116-47. doi: 10.1016/j.pharmthera.2007.04.007. Epub 2007 May 13. Pharmacol Ther. 2007. PMID: 17582504 Review.

• Metabotropic glutamate receptor 7: at the interface of cognition and emotion.

  O'Connor RM, Finger BC, Flor PJ, Cryan JF. O'Connor RM, et al. Eur J Pharmacol. 2010 Aug 10;639(1-3):123-31. doi: 10.1016/j.ejphar.2010.02.059. Epub 2010 Apr 2. Eur J Pharmacol. 2010. PMID: 20371242 Review.

• Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs.

  Wierońska JM, Pilc A. Wierońska JM, et al. Neurochem Int. 2009 Jul-Aug;55(1-3):85-97. doi: 10.1016/j.neuint.2009.02.019. Epub 2009 Mar 9. Neurochem Int. 2009. PMID: 19428811 Review.

• Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.

  Chaki S. Chaki S. Eur J Pharmacol. 2010 Aug 10;639(1-3):59-66. doi: 10.1016/j.ejphar.2009.12.041. Epub 2010 Apr 2. Eur J Pharmacol. 2010. PMID: 20371240 Review.

• Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.

  Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE. Johnson MP, et al. Biochem Soc Trans. 2004 Nov;32(Pt 5):881-7. doi: 10.1042/BST0320881. Biochem Soc Trans. 2004. PMID: 15494040 Review.

Cited by

• N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats.

  Lovell KM, Felts AS, Rodriguez AL, Venable DF, Cho HP, Morrison RD, Byers FW, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Emmitte KA. Lovell KM, et al. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3713-8. doi: 10.1016/j.bmcl.2013.05.020. Epub 2013 May 17. Bioorg Med Chem Lett. 2013. PMID: 23727046 Free PMC article.

• Adults with attention-deficit/hyperactivity disorder - a brain magnetic resonance spectroscopy study.

  Dramsdahl M, Ersland L, Plessen KJ, Haavik J, Hugdahl K, Specht K. Dramsdahl M, et al. Front Psychiatry. 2011 Nov 23;2:65. doi: 10.3389/fpsyt.2011.00065. eCollection 2011. Front Psychiatry. 2011. PMID: 22131979 Free PMC article.

• mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?

  Dravolina OA, Zvartau E, Danysz W, Bespalov AY. Dravolina OA, et al. Psychopharmacology (Berl). 2017 May;234(9-10):1333-1345. doi: 10.1007/s00213-017-4581-1. Epub 2017 Mar 11. Psychopharmacology (Berl). 2017. PMID: 28285325 Review.

• mGluR1-Dependent Long Term Depression in Rodent Midbrain Dopamine Neurons Is Regulated by Neuregulin 1/ErbB Signaling.

  Ledonne A, Mercuri NB. Ledonne A, et al. Front Mol Neurosci. 2018 Oct 1;11:346. doi: 10.3389/fnmol.2018.00346. eCollection 2018. Front Mol Neurosci. 2018. PMID: 30327588 Free PMC article.

• Distinct Time-Course of Alterations of Groups I and II Metabotropic Glutamate Receptor and GABAergic Receptor Expression Along the Dorsoventral Hippocampal Axis in an Animal Model of Psychosis.

  Dubovyk V, Manahan-Vaughan D. Dubovyk V, et al. Front Behav Neurosci. 2019 May 8;13:98. doi: 10.3389/fnbeh.2019.00098. eCollection 2019. Front Behav Neurosci. 2019. PMID: 31139061 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information